## 6.3 Assignment to Study Intervention

Patients will be centrally and randomly assigned to receive either apixaban or dalteparin.
The protocol will include procedures for switching between treatments:
*
Switching from vitamin K antagonist (VKA) therapy to Apixaban:
When converting pa
‐
tients from VKA therapy to Apixaban, warfarin or other VKA therapy should be discontinued and
Apixaban started when the international normalised ratio (INR) is < 2.
*
Switching from Apixaban to VKA therapy:
When converting patients from Apixaban to VKA
therapy, administration of Apixaban should be continued for at least 2 days after beginning VKA
therapy. After 2 days of coadministration, an INR should be obtained prior to the next scheduled
dose of Apixaban. Coadministration should be continued until the INR is ≥ 2.